-
Mashup Score: 12Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma - 1 month(s) ago
Although the burden of alcohol-associated hepatocellular carcinoma (HCC) is increasing with rising alcohol consumption, clinical presentation and outcomes of alcohol-associated HCC have not been systematically assessed. We aimed to determine the prevalence, clinical characteristics, surveillance rates, treatment allocation, and outcomes of alcohol-associated HCC.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 27
Metabolic dysfunction–associated steatotic liver disease affects 1 in 4 people in the United States and western Europe, with an important proportion developing metabolic dysfunction–associated steatohepatitis (MASH), the progressive subtype of metabolic dysfunction–associated steatotic liver disease. Cirrhosis caused by MASH is a leading indication for liver transplantation and the most common cause of hepatocellular carcinoma. Hitherto, there have been no specific pharmacotherapies for MASH. The recent conditional approval by the Food and Drug Administration of resmetirom for the treatment of moderate or advanced MASH presents a much-anticipated therapeutic option for patients with noncirrhotic advanced MASH.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
Editor's Essential Reading presents Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis ➡️ https://t.co/QtmMp4ldql https://t.co/DIssKL8GP4
-
-
Mashup Score: 12
Metabolic dysfunction–associated steatotic liver disease affects 1 in 4 people in the United States and western Europe, with an important proportion developing metabolic dysfunction–associated steatohepatitis (MASH), the progressive subtype of metabolic dysfunction–associated steatotic liver disease. Cirrhosis caused by MASH is a leading indication for liver transplantation and the most common cause of hepatocellular carcinoma. Hitherto, there have been no specific pharmacotherapies for MASH. The recent conditional approval by the Food and Drug Administration of resmetirom for the treatment of moderate or advanced MASH presents a much-anticipated therapeutic option for patients with noncirrhotic advanced MASH.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
RT @KralJan: 🚨 New Expert Panel Recomm. Alert 🚨 🔗📗 https://t.co/nQZmYP8ws9 💡Expert panel shares practical tips on initiating & monitoring…
-
-
Mashup Score: 15Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD - 1 month(s) ago
Metabolic dysfunction associated steatotic liver disease (MASLD) has a strong genetic component. The aim of this study was to examine noninvasively the prevalence of MASLD and of advanced fibrosis in relatives of patients with advanced MASLD and the risk factors for liver involvement, with a focus on the contribution of common genetic risk variants.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
High risk of steatotic liver disease in relatives of patients with advanced fibrosis: role of metabolic and genetic factors ➡️ https://t.co/KSFZzLsblT https://t.co/jgCDGyU8MO
-
-
Mashup Score: 27Updated Reference Intervals for Alanine Aminotransferase in a Metabolically and Histologically Normal Population - 1 month(s) ago
This study aims to reevaluate upper reference limit (URL) for alanine aminotransferase (ALT) by considering the changing epidemiology of major liver diseases. We employed histological and metabolic parameters in Asian living liver donors.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
👉 Updated Reference Intervals for Alanine Aminotransferase in a Metabolically and Histologically Normal Population: https://t.co/eRBKXviAjv https://t.co/6hBaYxYAC2
-
-
Mashup Score: 6Updated Reference Intervals for Alanine Aminotransferase in a Metabolically and Histologically Normal Population - 1 month(s) ago
This study aims to reevaluate upper reference limit (URL) for alanine aminotransferase (ALT) by considering the changing epidemiology of major liver diseases. We employed histological and metabolic parameters in Asian living liver donors.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
RT @CarlKayMD: NORMAL Alanine Aminotransferase (ALT) ▪️34 U/L for male ▪️22 U/L for female 🔗 https://t.co/e1a2Y9luEf 🙏 @AGA_CGH
-
-
Mashup Score: 9Association of Ultra-processed Food and Unprocessed or Minimally Processed Food Consumption With Bowel Habits Among U.S. Adults - 2 month(s) ago
Ultra-processed foods (UPFs) may have a negative impact on bowel habits. We aimed to assess the association between UPF and unprocessed or minimally processed food (MPF) intake and bowel habits among adults in the United States (U.S.).
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
Greater UPF intake is associated with increased odds of constipation. Greater MPF intake is associated with decreased odds of constipation https://t.co/xktL32J3w6 @ChunHanLoMDMPH https://t.co/0qcR5XqP3T
-
-
Mashup Score: 24Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial - 2 month(s) ago
The impact of thiopurine de-escalation while on vedolizumab versus continuing thiopurine therapy in ulcerative colitis (UC) is unclear. We aimed to determine the effect of thiopurine withdrawal for patients with UC in remission on vedolizumab.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
Although thiopurines do not affect vedolizumab levels, there is a higher risk of relapse when de-escalating thiopurines from patients with #UC on vedolizumab if they have had prior anti-TNF exposure or histological activity at baseline https://t.co/ndrJ4rduTr @rupertleong https://t.co/mXR9abwcdp
-
-
Mashup Score: 13Risk of Kidney Failure in Patients With Inflammatory Bowel Disease Undergoing Colectomy: A Nationwide Cohort Study - 2 month(s) ago
Inflammatory bowel disease (IBD) is frequently accompanied by kidney complications. Potential triggers or subpopulations at high-risk of kidney problems are not well-elucidated. We hypothesized that surgical interventions, specifically colectomy, might in part explain this risk.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
Study reports that those undergoing colectomy were at a higher risk of both acute kidney injury and kidney failure, particularly following total colectomy or colectomy with a prolonged stoma https://t.co/9Xf86xCHCW @yuanhang_yang @jjcarrero1 https://t.co/QGbyvLp1n6
-
-
Mashup Score: 15Development and Validation of a Score to Assess Transmural Healing and Response in Patients With Crohn’s Disease - 2 month(s) ago
Because transmural healing (TH) could be the best therapeutic target in Crohn’s disease (CD), we aimed to build and validate a score to assess TH and transmural response (TR), and to confirm their association with favorable CD outcomes.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet-
Development and Validation of a Score to Assess Transmural Healing and Response in Patients With #Crohn’s Disease ➡️ https://t.co/geJaFisKmY https://t.co/nRBbYYNnDD
-
These data call for measures to reduce heavy alcohol consumption and improve strategies for effective HCC surveillance in high-risk individuals ➡️ https://t.co/9Z5ZEvkZz6 https://t.co/WkC5VOB60c